Abstract Number: 0738 • ACR Convergence 2023
A Genome-wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome
Background/Purpose: Primary antiphospholipid syndrome (PAPS) is a rare autoimmune disease characterized by the presence of antiphospholipid antibodies and the occurrence of thrombotic events and pregnancy…Abstract Number: 0103 • ACR Convergence 2023
Criteria and Non-criteria Antiphospholipid Autoantibodies Screening in Women with Unexplained Fetal Death, Pre-eclampsia And/or Fetal Growth Restriction: A Cross-sectional Study
Background/Purpose: Antiphospholipid syndrome (APS) is a cause of pregnancy morbidity. Late pregnancy morbidity occurs in up to 25% of pregnant women with APS and may…Abstract Number: 0912 • ACR Convergence 2023
Inadequate Screening for Antiphospholipid Syndrome with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus
Background/Purpose: Antiphospholipid Syndrome (APS) is classified into primary and secondary; the latter being associated with connective tissue disease. Systemic lupus erythematosus (SLE) is the most…Abstract Number: 0104 • ACR Convergence 2023
Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study
Background/Purpose: Antiphospholipid antibodies (aPLs) play a pivotal role in the etiology of adverse pregnancy outcomes (APOs). (1) Women with persistently aPLs positivity present heterogeneous clinical…Abstract Number: 1208 • ACR Convergence 2023
Investigating the Experiences of Patients Living with Antiphospholipid Antibodies: A Qualitative Study
Background/Purpose: Substantial morbidity and mortality affect those with aPLs and APS, yet the patient experience remains poorly understood. This research investigated patient experiences of aPL/APS…Abstract Number: 0105 • ACR Convergence 2023
Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis
Background/Purpose: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by the presence of pathogenic autoantibodies. The key immune cell subsets change in PAPS patients…Abstract Number: 1467 • ACR Convergence 2023
Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is one of the most devastating complications of SLE. The exact pathogenesis leading to DAH in SLE is not well…Abstract Number: 0106 • ACR Convergence 2023
Positive Antiphospholipid Antibodies Are Associated with a Higher Risk of Cerebral Microbleeds
Background/Purpose: Persistent presence of antiphospholipid antibodies (aPLs) are important thrombosis-related laboratory parameters, as well as an indication of anticoagulation use which usually cause higher bleeding…Abstract Number: 1603 • ACR Convergence 2023
Infection-Associated Antiphospholipid Antibodies and Their Potential Role in Sepsis Outcomes
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia characterized by circulating antiphospholipid antibodies (aPL). While the association between aPL and infection has long been…Abstract Number: 0107 • ACR Convergence 2023
Impact of Antiphospholipid Syndrome on Mortality of Hospitalized Ischemic Stroke Patients: A Retrospective Analysis of the National Inpatient Sample Database 2020
Background/Purpose: Antiphospholipid syndrome (APS) is recognized for its association with an elevated risk of ischemic strokes and other thromboembolic events. This study aims to compare…Abstract Number: 1604 • ACR Convergence 2023
First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: The APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with or…Abstract Number: 0686 • ACR Convergence 2022
Anti-β2GP1/HLA-DR Antibody Is Associated with Arterial Thrombosis in Female Patients with Connective Tissue Diseases: A Cross-Sectional Study in Japan
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and/or pregnancy complications. Recently, β2-glycoprotein I (β2GPI) complexed with HLA class II molecules (β2GPI/HLA-DR)…Abstract Number: 2268 • ACR Convergence 2022
Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: Long-term anticoagulation is the standard of care for antiphospholipid syndrome (APS) patients with macrovascular thrombosis. However, in daily practice, long-term anticoagulation may not be…Abstract Number: 0671 • ACR Convergence 2022
Thrombocytopenia and Autoimmune Hemolytic Anemia in Antiphospholipid Antibody-positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: The APS ACTION Registry was created to study the natural course of antiphospholipid syndrome (APS) over 10 years in persistently antiphospholipid antibody (aPL) positive…Abstract Number: 0687 • ACR Convergence 2022
DNA- and NET-Binding Beta-2 Glycoprotein I in a Large Cohort of Antiphospholipid Antibody-Positive Patients
Background/Purpose: Beta-2 glycoprotein I (β2GPI) is an abundant plasma protein and a critically important autoantigen in APS. While β2GPI has been reported to have antioxidant,…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 23
- Next Page »